Milind M. Javle
Department of Gastrointestinal Medical Oncology
UT-M D Anderson Cancer Center
Houston
USA
Name/email consistency: high
- Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. Javle, M.M., Shroff, R.T., Xiong, H., Varadhachary, G.A., Fogelman, D., Reddy, S.A., Davis, D., Zhang, Y., Wolff, R.A., Abbruzzese, J.L. BMC. Cancer (2010)
- Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis. Javle, M.M., Yang, G., Nwogu, C.E., Wilding, G.E., O'Malley, L., Vinjamaram, S., Schiff, M.D., Nava, H.R., LeVea, C., Clark, K.R., Prey, J.D., Smith, P.F., Pendyala, L. Cancer Invest. (2009)
- Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. Javle, M., Yu, J., Garrett, C., Pande, A., Kuvshinoff, B., Litwin, A., Phelan, J., Gibbs, J., Iyer, R. Br. J. Cancer (2009)
- Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. Javle, M., Hsueh, C.T. J. Hematol. Oncol (2009)
- Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response. Javle, M., Pande, A., Iyer, R., Yang, G., LeVea, C., Wilding, G., Black, J., Nava, H., Nwogu, C. Am. J. Clin. Oncol. (2008)
- Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil. Javle, M.M., Cao, S., Durrani, F.A., Pendyala, L., Lawrence, D.D., Smith, P.F., Creaven, P.J., Noel, D.C., Iyer, R.V., Rustum, Y.M. Clin. Cancer Res. (2007)
- Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer. Javle, M.M., Gibbs, J.F., Iwata, K.K., Pak, Y., Rutledge, P., Yu, J., Black, J.D., Tan, D., Khoury, T. Ann. Surg. Oncol. (2007)
